The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 05, 2017

Filed:

Oct. 27, 2016
Applicant:

Scinopharm Taiwan, Ltd., Tainan, TW;

Inventors:

Tsung-Yu Hsiao, Tainan, TW;

MengFen Ho, Tainan, TW;

HsinChang Tseng, Tainan, TW;

WenShing Tsao, Tainan, TW;

YuanChang Huang, Tainan, TW;

Wei-Shuo Lo, Tainan, TW;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 43/90 (2006.01); A61K 31/519 (2006.01); C07D 487/00 (2006.01); C07D 487/04 (2006.01); C07F 9/6561 (2006.01); C07D 401/04 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); A61K 31/519 (2013.01); C07D 401/04 (2013.01); C07F 9/6561 (2013.01);
Abstract

The present invention provides efficient, economical, and improved methods for synthesizing ibrutinib and intermediates thereof. The invention involves a unique biphasic acylation reaction system which advantageously allows for easy separation of ibrutinib from the reaction mixture without additional extraction and wash steps. The isolated ibrutinib formed using the methods described herein can be useful in the preparation of an amorphous form of ibrutinib. In some embodiments, the isolated ibrutinib produced by the processes described herein is a homogenous solution of ibrutinib and DMSO which may be directly used in the formation of the amorphous polymorph. In some embodiments, the isolated ibrutinib is solid ibrutinib. The solid ibrutinib may also be used in the formation of amorphous ibrutinib.


Find Patent Forward Citations

Loading…